Patents by Inventor Melissa Adams
Melissa Adams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230252415Abstract: Systems and methods to recommend templates for project-level graphical user interfaces within a collaboration environment are described herein. Exemplary implementations may: manage environment state information maintaining a collaboration environment; manage information defining project-level graphical user interfaces; monitor use of the collaboration environment by the users determined metric values for use metrics of the users; create templates for the project-level graphical user interfaces based on the metric values; generate and deliver template recommendations for the project-level graphical user interfaces; effectuate presentation of the project-level graphical user interfaces for the individual projects in the collaboration environment; and/or perform other operations.Type: ApplicationFiled: April 21, 2023Publication date: August 10, 2023Inventors: Nicole Jazmin Ackerman-Greenberg, Melissa Adams, Benjamin Henry Watkins, Chelsea Renee Padgham
-
Patent number: 11694162Abstract: Systems and methods to recommend templates for project-level graphical user interfaces within a collaboration environment are described herein. Exemplary implementations may: manage environment state information maintaining a collaboration environment; manage information defining project-level graphical user interfaces; monitor use of the collaboration environment by the users determined metric values for use metrics of the users; create templates for the project-level graphical user interfaces based on the metric values; generate and deliver template recommendations for the project-level graphical user interfaces; effectuate presentation of the project-level graphical user interfaces for the individual projects in the collaboration environment; and/or perform other operations.Type: GrantFiled: April 1, 2021Date of Patent: July 4, 2023Assignee: Asana, Inc.Inventors: Nicole Jazmin Ackerman-Greenberg, Melissa Adams, Benjamin Henry Watkins, Chelsea Renee Padgham
-
Publication number: 20220188715Abstract: Systems and methods for measuring and visualizing threshold of user workload. Exemplary implementations may: manage environment state information describing units of work assigned to individual users within the collaboration environment, individual units of work having individual start dates and individual end dates; determine threshold information including individual values of a threshold parameter for the individual users; effectuate presentation of a user interface based on the values of the work unit parameter, the values of the threshold parameter for the individual users, and/or other information; and/or perform other operations.Type: ApplicationFiled: March 1, 2022Publication date: June 16, 2022Inventors: Ye Cheng, Matthew Stevens, Melissa Adams
-
Publication number: 20220188279Abstract: Systems and methods for creating and tracking implementation of a consolidation of data during a migration from one or more source systems to one target system are described herein. One system includes a computing device, having a processor and memory, and instructions stored in memory that are executable by the processor wherein a set of software objects and their attributes are identified based on metadata of the target system, a first subset of the software objects is selected to identify information needing to be migrated from a first source system of the one or more source systems to the target system, and a second subset of the software objects is selected to identify information needing to be migrated from a first source system of the one or more source systems to the target system, and wherein the first and second subsets are merged together to form a merged subset.Type: ApplicationFiled: December 11, 2020Publication date: June 16, 2022Inventors: Umadevi Krishnaraju, Melissa Adams, Levi Paulson
-
Patent number: 11341445Abstract: Systems and methods for measuring and visualizing threshold of user workload. Exemplary implementations may: manage environment state information describing units of work assigned to individual users within the collaboration environment, individual units of work having individual start dates and individual end dates; determine threshold information including individual values of a threshold parameter for the individual users; effectuate presentation of a user interface based on the values of the work unit parameter, the values of the threshold parameter for the individual users, and/or other information; and/or perform other operations.Type: GrantFiled: November 14, 2019Date of Patent: May 24, 2022Assignee: Asana, Inc.Inventors: Ye Cheng, Matthew Stevens, Melissa Adams
-
Patent number: 11248209Abstract: This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g.Type: GrantFiled: December 20, 2016Date of Patent: February 15, 2022Assignee: CoImmune, Inc.Inventors: Don Healey, Irina Tcherepanova, Melissa Adams
-
Patent number: 10184108Abstract: This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g.Type: GrantFiled: December 19, 2016Date of Patent: January 22, 2019Assignee: Argos Therapeutics, Inc.Inventors: Don Healey, Irina Tcherepanova, Melissa Adams, Mark Debenedette
-
Publication number: 20170096640Abstract: This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g.Type: ApplicationFiled: December 20, 2016Publication date: April 6, 2017Inventors: Don HEALEY, Irina Tcherepanova, Melissa Adams
-
Publication number: 20170096639Abstract: This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g.Type: ApplicationFiled: December 19, 2016Publication date: April 6, 2017Inventors: Don HEALEY, Irina Tcherepanova, Melissa Adams, Mark Debenedette
-
Patent number: 9556455Abstract: This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g.Type: GrantFiled: August 29, 2014Date of Patent: January 31, 2017Assignee: Argos Therapeutics, Inc.Inventors: Don Healey, Irina Tcherepanova, Melissa Adams
-
Patent number: 9523077Abstract: This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g.Type: GrantFiled: July 15, 2013Date of Patent: December 20, 2016Assignee: Argos Therapeutics, Inc.Inventors: Don Healey, Irina Tcherepanova, Melissa Adams, Mark DeBenedette
-
Publication number: 20160319374Abstract: Provided herein are compositions, methods, and kits for detection of Entamoeba nucleic acids. Some embodiments relate to detection of E. histolytica but not E. dispar. Some embodiments relate to quantification of levels of E. histolytica.Type: ApplicationFiled: December 30, 2014Publication date: November 3, 2016Inventors: Steven Knapp, Charlotte Brown, Karen Lenz, Melissa Adams, Robert Swan
-
Publication number: 20150072431Abstract: This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g.Type: ApplicationFiled: August 29, 2014Publication date: March 12, 2015Inventors: Don HEALEY, Irina Tcherepanova, Melissa Adams, Atsushi Hinohara
-
Patent number: 8822223Abstract: This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g.Type: GrantFiled: October 7, 2005Date of Patent: September 2, 2014Assignee: Argos Therapeutics, Inc.Inventors: Don Healey, Irina Tcherepanova, Melissa Adams
-
Publication number: 20140017788Abstract: This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g.Type: ApplicationFiled: July 15, 2013Publication date: January 16, 2014Applicant: ARGOS THERAPEUTICS, INC.Inventors: Don Healey, Irina Tcherepanova, Melissa Adams, Mark DeBenedette
-
Patent number: 8513008Abstract: This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g.Type: GrantFiled: April 7, 2006Date of Patent: August 20, 2013Assignee: Argos Therapeutics, Inc.Inventors: Irina Tcherepanova, Melissa Adams
-
Publication number: 20120269832Abstract: This invention provides novel CD40L polypeptides and nucleic acids, as well as antigen presenting cells and vaccines comprising such CD40L polypeptides and/or nucleic acids, and related methods for preparing the antigen presenting cells and vaccines. The antigen presenting cells and vaccines are useful for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention.Type: ApplicationFiled: April 6, 2007Publication date: October 25, 2012Inventors: Donald Healey, Irina Tcherepanova, Atsushi Hinohara, Melissa Adams, Mark DeBenedette
-
Patent number: 8060539Abstract: The present invention provides a method for notifying at least one invitee of an initial event of changes to the initial event. The method comprises receiving the initial event comprising a plurality of initial event elements and receiving an updated event comprising a plurality of updated event elements, each updated event element corresponding to a respective initial event element. The updated event elements are compared to the initial event elements to determine which of the updated event elements are changed event elements that differ from their respective initial event elements and the at least one invitee is notified of any specific changed event elements.Type: GrantFiled: February 24, 2005Date of Patent: November 15, 2011Assignee: Research in Motion LimitedInventors: Neil Adams, Herb Little, Melissa Adams
-
Publication number: 20080145931Abstract: This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g.Type: ApplicationFiled: October 7, 2005Publication date: June 19, 2008Inventors: Donald Healey, Irina Tcherepanova, Atsushi Hinohara, Melissa Adams
-
Publication number: 20070082400Abstract: This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g.Type: ApplicationFiled: April 7, 2006Publication date: April 12, 2007Inventors: Donald Healey, Irina Tcherepanova, Melissa Adams, Atsushi Hinohara, Mark DeBenedette